IP Library Granted Patent US 9,913,866
Granted Patent B2
US 9,913,866 · App. 14/485,472 · Granted Mar 13, 2018

Selective cell targeting using adenovirus and chemical dimers

Inventors: Clodagh O'Shea (San Diego, CA); Shigeki Miyake-Stoner (La Jolla, CA); Colin Powers (San Diego, CA)
Assignee: Salk Institute for Biological Studies
A61K35/761C12N7/00C12N15/86C07K2319/20C12N2710/10034C12N2710/10052C12N2710/10345
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,913,866
App. No.
14/485,472
Granted
Mar 13, 2018
Kind
B2
Abstract

Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.

Claims (12)

1. A recombinant adenovirus comprising a recombinant nucleic acid encoding a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate, wherein the capsid-dimerizing agent binder conjugate comprises an adenoviral fiber protein and a FRB protein inserted into the H1 loop of the adenoviral fiber protein, and the ligand-dimerizing agent binder conjugate comprises a ligand and a FKBP protein,

wherein the FRB protein is encoded by the nucleotide sequence of SEQ ID NO: 69 and the FKBP protein is at least 90% identical to the FKBP protein encoded by SEQ ID NO: 66,

and wherein said insertion of the FRB protein into the H1 loop of the adenoviral fiber protein does not inhibit replication and assembly of the adenovirus.

2. The recombinant adenovirus of claim 1 , wherein the ligand is capable of binding a tumor cell.

3. The recombinant adenovirus of claim 1 , wherein the ligand is an antibody.

4. The recombinant adenovirus claim 3 , wherein the antibody is a single domain antibody.

5. The recombinant adenovirus of claim 1 , wherein the FKBP protein is a human FKBP protein.

6. The recombinant adenovirus of claim 5 , wherein the human FKBP protein is FKBP12.

7. A recombinant adenovirus comprising a capsid-dimerizing agent binder conjugate, wherein the capsid-dimerizing agent binder conjugate comprises an adenoviral fiber protein and a FRB protein inserted into the H1 loop of the adenoviral fiber protein, wherein the FRB protein is encoded by the nucleotide sequence of SEQ ID NO: 69, and wherein said insertion of the FRB protein into the H1 loop of the adenoviral fiber protein does not inhibit replication and assembly of the adenovirus.

8. The recombinant adenovirus of claim 7 , wherein the capsid-dimerizing agent binder conjugate is bound to a dimerizing agent.

9. The recombinant adenovirus of claim 8 , wherein the dimerizing agent is further bound to a ligand-dimerizing agent binder conjugate, wherein the ligand-dimerizing agent binder conjugate comprises a ligand and a FKBP protein at least 90% identical to the FKBP protein encoded by SEQ ID NO: 66.

10. The recombinant adenovirus of claim 8 , wherein the dimerizing agent is rapamycin or a rapalog.

Assignments (2)
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 2, 2026
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 074994/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2014
From: O'SHEA, CLODAGH; MIYAKE-STONER, SHIGEKI; POWERS, COLIN
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 033806/0447 →
Continuity (3)
Continuation PCTUS2013031002 · Mar 13, 2013
Provisional Application 61610416 · Mar 13, 2012
Related Publication 20150017127A1 · Jan 15, 2015